Company Name: ADmit Therapeutics
Year Founded: 2017
Location: Barcelona, Spain
Total Funding: €8M in funding over 5 rounds
What is the challenge being tackled?
Alzheimer’s disease is a progressive condition that affects multiple brain functions. It develops gradually over many years and eventually becomes more severe. One significant challenge is detecting Alzheimer's disease in its early stages. ADmit Therapeutics specializes in pioneering a groundbreaking technology for the early detection of Alzheimer's disease (AD) and its subsequent commercialization.
Despite the pressing need, there is a notable absence of in vitro diagnostic devices (IVDRs) for early AD detection integrated into clinical practice. ADmit Therapeutics seeks to address this gap through its innovative approach, offering hope for earlier intervention and improved outcomes in the management of Alzheimer's disease.
Company Official Description:
"Our IVDR represents the determination of biomarkers non-related with β-amyloid nor tau. Therefore, our unique value proposition is that our technology is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next generation sequencing. As systemic mitochondrial dysfunction has been proposed just before the appearance of cerebral abnormal protein aggregates, our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD."
Core Features
ADmit Therapeutics plans to offer its in vitro diagnostic (IVD) test to pharmaceutical firms, streamlining patient recruitment for clinical trials. This streamlined process aims to enhance the identification of effective treatments for Alzheimer's disease (AD). Additionally, the company intends to extend its efforts to complementary areas like Dementia with Lewy bodies and Parkinson's Disease, diversifying its portfolio for maximum impact.
1. Innovative IVD Test
ADmit Therapeutics specializes in developing and offering an innovative in vitro diagnostic (IVD) test for the early detection of Alzheimer's disease (AD). This test utilizes advanced technology and biomarker analysis to provide accurate and timely diagnoses.
2. Clinical Trial Optimization
The company's IVD test is designed to optimize patient recruitment for clinical trials conducted by pharmaceutical companies. By facilitating efficient recruitment, ADmit Therapeutics aims to accelerate the development and identification of effective drugs for AD treatment.
3. Complementary Focus Areas
ADmit Therapeutics extends its expertise beyond Alzheimer's disease to complementary fields such as Dementia with Lewy bodies and Parkinson's Disease. By diversifying its focus areas, the company aims to strengthen its offerings and appeal to a broader range of stakeholders and potential acquirers.
The company is committed to ongoing innovation and improvement in the field of AD detection and management. This may include the development of new technologies, refinement of existing diagnostic tools, and adaptation to emerging trends and research findings in Alzheimer's disease. Exciting times ahead, good luck #ADmit !